SCHEMBL1334862

SCHEMBL1334862

O=C(Nc1ccccc1)OCc1ccncc1

nearest known ligand 0.88

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.88
NAMPT P43490 2/20 0.64
NPC1 O15118 2/20 0.61
RAB9A P51151 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
LMNA P02545 1/20 0.61
MGLL Q99685 2/20 0.60
TDP1 Q9NUW8 1/20 0.57
HTT P42858 1/20 0.56
ROCK2 O75116 1/20 0.56
TP53 P04637 1/20 0.55
MAPT P10636 1/20 0.55
TAAR1 Q96RJ0 1/20 0.54
ENPP2 Q13822 1/20 0.53
KDM1A O60341 1/20 0.53
MAOA P21397 1/20 0.53
MAOB P27338 1/20 0.53
CHRNA7 P36544 1/20 0.53
RECQL P46063 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13679756 0.94 POLB (1.00) POLBNAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL1665485 0.92 POLB (0.84) POLBNAMPTNPC1RAB9ASMN1; SMN2
Benzyl Phenylcarbamate SCHEMBL1222943 0.88 POLB (0.78) POLBNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL10595799 0.88 POLB (0.73) POLBNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL10259763 0.88 POLB (0.83) POLBNAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL1665313 0.86 POLB (0.67) POLBNAMPTNPC1RAB9ALMNA
SCHEMBL31044012 0.86 POLB (0.70) POLBNAMPTNPC1RAB9ASMN1; SMN2
SCHEMBL8202632 0.84 NAMPT (0.73) POLBNAMPTNPC1RAB9ASMN1; SMN2
Benzyl Phenylcarbamate SCHEMBL2635177 0.83 POLB (0.71) POLBNPC1RAB9ASMN1; SMN2LMNA
SCHEMBL2056382 0.83 NAMPT (0.76) POLBNAMPTNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US claimed
CN-102143747-A New pyridine derivatives as leptin receptor modulator mimetics ASTRAZENECA AB 2011-08-03 CN claimed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP claimed
WO-2009147216-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS BIOVITRUM AB (PUBL) (SE) 2009-12-10 WO claimed
EP-2102189-B1 ARYLPROPIONAMIDE, ARYLACRYLAMIDE, ARYLPROPYNAMIDE, OR ARYLMETHYLUREA ANALOGS AS FACTOR XIA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2015-07-29 EP disclosed
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US disclosed
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US disclosed
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics BIOVITRUM AB (SE) 2011-11-10 US disclosed
CN-102143747-A New pyridine derivatives as leptin receptor modulator mimetics ASTRAZENECA AB 2011-08-03 CN disclosed
EP-2313094-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS AstraZeneca AB (SE) 2011-04-27 EP disclosed
WO-2009147216-A1 NEW PYRIDINE DERIVATIVES AS LEPTIN RECEPTOR MODULATOR MIMETICS BIOVITRUM AB (PUBL) (SE) 2009-12-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110275678-A1 New Pyridine Derivatives as Leptin Receptor Modulator Mimetics GPR119, GLP1R, ADIPOR1 POLB 4125/4885NAMPT 531/4885NPC1 2854/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.